linjc16/ctgov huggingface dataset:
Functional Performance Following Emergency High-risk Abdominal Surgery

Study Overview
=================
Brief Summary
-----------------
Emergency abdominal surgery is associated with high mortality rates, multiple postoperative complications and prolonged duration of hospital admission. The purpose of this study is to examine the postoperative functional performance in patients undergoing Emergency High-risk Abdominal Surgery. The hypothesis is that the study can describe the patient population in relation to postoperative functioning, degree of inactivity and the factors that limit mobility.

Official Title
-----------------
Functional Performance Following Emergency High-risk Abdominal Surgery

Conditions
-----------------
Emergency High-risk Abdominal Surgery

Intervention / Treatment
-----------------
* Other: Evaluation of functional performance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients (19 years and older) undergoing emergency laparotomy or laparoscopy (inclusive reoperations after elective surgery). Exclusion Criteria: Patients undergoing minor emergency operations (uncomplicated appendectomy, laparoscopic cholecystectomy, diagnostic laparoscopy or laparotomy without intervention)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Emergency High-risk Abdominal Surgery<br> | Other: Evaluation of functional performance<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Basic mobility evaluated by the Cumulated Ambulation Score (CAS) | Factors that limit independency in basic mobility will be evaluated on a daily basis. | Daily on postoperative day 1 to 7 and at discharge from the hospital (average length of stay is: 14 days). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physical activity assessment with accelerometer (ActivePAL) |  | Daily on postoperative day 1 to 7. | 
| Visual Analog Scale (VAS) | VAS is a self-reported measure of pain intensity. | Daily on postoperative day 1 to 7 and at discharge from the hospital (average length of stay is: 14 days). | 
| Assessment of Motor and Process Skills (AMPS) | AMPS measures a person's performance capacity for activities of daily living (ADL) and/or independent living. | One time at postoperative day 4. |
Lack of Antenatal Care in Primiparas

Study Overview
=================
Brief Summary
-----------------
Antenatal care is a key strategy for reducing maternal and neonatal morbidity and mortality rate because adequate utilization of antenatal health care services is associated with improved maternal and neonatal health outcomes. The trend of maternal mortality in developing countries has been increasing and various international organizations have reported that an important factor related to maternal and infant mortality has been linked to lack of antenatal care. According to Federal Ministry of Health, some of the dangers of pregnancy and childbirth can be avoided if the pregnant woman attends antenatal regularly. In order to decrease these mortality rates, regular antenatal care has to be instituted or reinforced which can only be achieved through identifying factors causing poor utilization of antenatal care services

Official Title
-----------------
Impact of Lack of Antenatal Care in Primiparas on Maternal and Perinatal Outcomes

Conditions
-----------------
Antenatal Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who agree to participate in the study Primipara. Exclusion Criteria: Multipara. Women who refuse to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of morbidity cases due to lack of antenatal care |  | 9 months |
ARTHRO Distension Plus Intensive Mobilisation in Shoulder Capsulitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effectiveness of ARTHRO distension plus intensive mobilisation in shoulder capsulitis.

Detailed Description
-----------------
The aim of the study is to evaluate a treatment of shoulder capsulitis that associates ARTHRO distension and intensive mobilisation at 2, 6, 12, 26 and 52 weeks. It is a bicentric 87-month (inclusion: 74 months; follow up: 13 months) observer blind randomised clinical trial using 2 groups in parallel. The number of patients to be included is 66. The treatment that is evaluated associates ARTHRO distension followed by mobilisation of the shoulder 6 hours per day during 5 days, and then sessions of physiotherapy for 4 weeks. The control intervention is one intra-articular injection of corticosteroids and physiotherapy. The primary outcome is SPADI, namely pain and disability, at 2 weeks.

Official Title
-----------------
Evaluation of the Effectiveness of ARTHRO -Distension Plus Intensive Mobilisation in Shoulder Capsulitis

Conditions
-----------------
Shoulder Capsulitis

Intervention / Treatment
-----------------
* Procedure: infiltration intra articular
* Procedure: ARTHRO distension plus intensive mobilisation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 years shoulder capsulitis duration of symptoms ≥ 3 months health insurance Exclusion Criteria: cognitive disorders Hypo coagulation biological inflammatory syndrome uncontrolled diabetes XYLOCAINE allergy pregnancy unable to understand and to speak french previous surgery of shoulder shoulder infiltration or distension in the previous month local contraindication to shoulder infiltration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>infiltration intra articular | Procedure: infiltration intra articular<br>* infiltration intra articular at inclusion with XYLOCAINE 1%<br>* Other names: infiltration intra articular at inclusion with XYLOCAINE 1%;|
| Experimental: 2<br>ARTHRO distension plus intensive mobilisation | Procedure: ARTHRO distension plus intensive mobilisation<br>* ARTHRO distension plus intensive mobilisation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain and disability using SPADI score at 2 weeks |  | at 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Shoulder capsulitis, ARTHRO distension, Mobilisation, Randomised clinical trial
Optic Nerve and Retinal Functions With Bevacizumab

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the possible affection of optic nerve and retinal functions following intravitreal bevacizumab injection in human eyes.

Detailed Description
-----------------
To evaluate the retinal and optic nerve functions of bevacizumab when injected intravitreal in human eyes using electrophysiological tests; Electroretinogram (ERG) and Visual Evoked Potentials (VEP). Forty five eyes of 45 patients with choroidal neovascular membrane (CNV) who were prepared for intravitreal injections of 1.25mg bevacizumab underwent baseline ERG and VEP in both eyes before, and at 1 and 4 weeks after the intravitreal injections.

Official Title
-----------------
Electrophysiological Assessment of Optic Nerve and Retinal Functions Following Intravitreal Injection of Bevacizumab (Avastin).

Conditions
-----------------
Choroidal Neovascular Membrane

Intervention / Treatment
-----------------
* Procedure: Electrophysiology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CNV Exclusion Criteria: Previous Intravitreal Injections

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 62 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with choroidal neovascularization<br>CNV due to Age-Related Macular Degenerations and Myopia were included. | Procedure: Electrophysiology<br>* Visual Evoked Potential and Elctroretinogram<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Evoked Potential and Electroretinogram | VEP and ERG baseline and at 1 and 4 weeks post intravitreal injection of bevacizumab. | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bevacizumab, VEP, ERG, Optic nerve and retinal functions following intravitreal bevacizumab
SPP100 Dose Finding Study in Japan

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.

Official Title
-----------------
Dose-finding Study of SPP100 in Essential Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Aliskiren


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mild to moderate essential hypertension Age: ≥20 years old and <80 years old (at time informed consent obtained) Sex: N/A Admission status: Outpatient Exclusion Criteria: Pregnant women, lactating women, potentially pregnant women, or women who wish to become pregnant Patients having a mean sitting diastolic blood pressure of ≥110 mmHg and/or a mean sitting systolic blood pressure of ≥180 mmHg at either Visit 2 or 3 Patients with secondary hypertension as a complication or patients suspected of having secondary hypertension(due to aortic coarctation, primary aldosteronism, coarctation of renal artery, renal hypertension Patients suspected of having malignant hypertension

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Aliskiren|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in mean sitting diastolic blood pressure after 8 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in mean sitting systolic blood pressure after 8 weeks |  |  | 
| Diastolic blood pressure less than 90 mmHg or 10 mmHg or greater change from baseline after 8 weeks |  |  | 
| Evaluate response to various doses by assessing the difference in mean sitting diastolic blood pressure after 8 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Aliskiren
The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
The aims of this study are to (1) understand the uncertainty , personality and coping strategies in patients with HCC, and identify the significant factors for coping.

Detailed Description
-----------------
A cross-sectional correlated design will be used and (2) patients will be recruited by purposive sampling from wards and outpatient departments at a medical center in Taipei.

Official Title
-----------------
The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma

Conditions
-----------------
Liver Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Has HCC and knows condition Con's clear Agree join the study Exclusion Criteria:e BCLC stage C or D Accepted C/T, R/T,target therapy or supportive care Patient who receive liver transplantation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver cancer, Uncertainty, Personality, coping strategies
Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric

Study Overview
=================
Brief Summary
-----------------
To allow surgeons to obtain clinical experience on the postoperative uncorrected and best distance corrected visual acuities (UCVA and BDCVA) and corneal and refractive cylinder of the AcrySof Toric IOL.

Conditions
-----------------
Cataract

Intervention / Treatment
-----------------
* Device: AcrySof® Toric IOL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40-80 years old; of any race and gender; diagnosed with bilateral cataracts; require cataract extraction followed by implantation of a posterior chamber IOL; patients have between 0.75 -2.5 D of astigmatism preoperatively as measured by K readings. Exclusion Criteria: Females of child bearing potential;irregular corneal astigmatism;keratopathy/Keratectasia; cornea inflammation or edema;previous corneal reshaping,dystrophy or transplant;amblyopia;glaucoma;RPE/Macular changes;diabetic retinopathy.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>AcrySof® Toric IOL | Device: AcrySof® Toric IOL<br>* Implanted into the study eye<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal astigmatism; IOL rotation |  | Before opertation; 1 day following implantation of each eye; 1, 3 months following lens implantation in the second eye. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uncorrected and best distance corrected visual acuities (UCVA and BDCVA) |  | Before opertation; 1 day following implantation of each eye; 1, 3 months following lens implantation in the second eye. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Visual acuity,, corneal and, refractive, cylinder, following, implantation of the, AcrySof® Toric
Treatment of Humeral Fractures With Long PHILOS Plates Using a Modified Technique and Approach Avoids Radial Nerve Palsy

Study Overview
=================
Brief Summary
-----------------
Radial paralysis is a well-known complication of plate osteosynthesis on the humeral shaft. At the University Hospital Basel, these fractures have been treated in an adapted procedure with long PHILOS plates using a modified technique and approach. This study is to retrospectively analyze the effectiveness of the surgical technique in relation to iatrogenic radial paralysis.

Detailed Description
-----------------
Radial paralysis is a well-known complication of plate osteosynthesis on the humeral shaft. With regard to surgical treatment, there are major differences in terms of surgical access and implant selection. At the University Hospital Basel, these fractures have been treated in an adapted procedure for about 10 years. A long Philosplatte (Synthes company) is inserted from the proximal end via a deltoido-pectoral approach. This is a minimally invasive procedure (MIPO = minimally invasive plate osteosynthesis). The standard implant is first twisted distally by approx. 45°-90° and then lies anterior to the humerus. The distal screws can then be filled via anterior stab incisions. This adapted surgical technique is adapted to the anatomical course of the radial nerve. This ensures a safe distance from the plate/access to the nerve. The nerve does not have to be explored openly and the distal row of screws can be used minimally invasively via stab incisions. This study is to retrospectively analyze the effectiveness of the surgical technique in relation to iatrogenic radial paralysis.

Official Title
-----------------
Treatment of Humeral Fractures With Long PHILOS Plates Using a Modified Technique and Approach Avoids Radial Nerve Palsy

Conditions
-----------------
Humeral Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: surgery at the University Hospital Basel between 06/2010 and 12/2020 for a proximal humeral shaft fracture Exclusion Criteria: Patients with a documented rejection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| descriptive statistical analysis of datasets from patients treated with the adapted surgical technique | datasets from patients (information about hospitalizations and risk factors, traumatological and orthopedic information (precise diagnosis and classification, date, number and type of operation, complications), infectious data (detection of germs, type and duration of therapy) | one time assessment at baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PHILOS plate, minimal invasive plate osteosynthesis (MIPO), radial paralysis
High Dose Nimodipine Treatment Adjunct - 1

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit.

Official Title
-----------------
High Dose Nimodipine Pharmacotherapy Adjunct

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Nimodipine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nimodipine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stimulated and non-stimulated craving |  |  | 
| Stimulated and non-stimulated withdrawal |  |  | 
| Anxiety, depression |  |  | 
| Heart rate |  |  |
Newborn Screening for Spinal Muscular Atrophy

Study Overview
=================
Brief Summary
-----------------
To test if the routine newborn screening dried blood spots can be used to test if missing 2 copies of SMN1 gene, a status indicating spinal muscular atrophy

Detailed Description
-----------------
Parents of newborns will be invited to test if their newborns are affected with SMA. The routine newborn screening dried blood spots sample will be used to test if missing 2 copies of SMN1 gene. If positive of screening test, further confirmation tests including physical examination and other methology for SMN1 gene copies quantification will be provided. Genetic counseling and treatment option will be provided, too.

Official Title
-----------------
Newborn Screening for Spinal Muscular Atrophy

Conditions
-----------------
Spinal Muscular Atrophy

Intervention / Treatment
-----------------
* Other: newborn screening test for SMA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Babies born in Taiwan receive regular new born screening suggested by Ministry of Heath and Welfare. Parents or Legal Guardian sign in the informed consent form. Exclusion Criteria: Parents or Legal Guardian do not agree to sign in the informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 2 Days
Maximum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| newborns testing for SMA<br> | Other: newborn screening test for SMA<br>* Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| numbers of newborn with spinal muscular atrophy |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Newborn Screening , spinal muscular atrophy